What question did this study set out to answer?

This research focuses on developing a novel gene transfer platform for CAR-T therapy using protein-based coacervates.

December 8, 2025BloodOpen Access

A mammalian protein-based coacervate platform enables scalable engineering for CAR-T therapy

View Full Paper

Ask AI

Bookmark

Authors

Innovation in CAR-T therapy reveals a mammalian protein-based coacervate system for efficient gene delivery and robust scalability.

This research focuses on developing a novel gene transfer platform for CAR-T therapy using protein-based coacervates.
Developed a coacervate-based gene delivery system (EASY) using mammalian proteins.
Assessed transfection efficiency and viability in primary human T lymphocytes.
Explored multiplexed gene editing using Cas9 and sgRNAs in T cells.
Scalability tests were performed for modifying large numbers of T cells.
Achieved over 90% mRNA transfection efficiency with 90% viability in T lymphocytes.
Generated CAR-T cells that effectively eliminated tumors in mouse models after a single dose.
Demonstrated over 80% gene editing efficiency for multiple loci in primary T cells.
Successfully scaled to modify over 10^9 primary human T cells while maintaining high delivery efficiency.

Renxia Zhang (2025) studied this question.

View Full Paper

Ask AI

Bookmark